← Back to Search

Microbiome Formulation

MET-3 for Obesity

Phase 1
Waitlist Available
Led By Thomas Wolever, MD/PhD
Research Sponsored by NuBiyota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs. week 7
Awards & highlights

Study Summary

This study is evaluating whether a probiotic and prebiotic combination can lower fasting serum triglycerides.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs. week 7
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline vs. week 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fasting blood lipid levels

Trial Design

2Treatment groups
Experimental Treatment
Group I: MET-5 2.5 g daily for 4 weeksExperimental Treatment1 Intervention
MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
Group II: MET-3 2.5 g daily for 4 weeksExperimental Treatment1 Intervention
MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.

Find a Location

Who is running the clinical trial?

NuBiyotaLead Sponsor
8 Previous Clinical Trials
221 Total Patients Enrolled
1 Trials studying Obesity
15 Patients Enrolled for Obesity
Thomas Wolever, MD/PhDPrincipal InvestigatorINQUIS Clinical Research

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia
2020. "Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04507971.
All > Microbiome
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top